Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 9

Optimizing Therapy Selection in EGFR Mutant NSCLC

July 22, 2024

Mark A. Socinski, MD, Helena A. Yu, MD, Zosia Piotrowska, MD, MHS , Julia Rotow, MD, Benjamin Levy, MD

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for NSCLC with Non-Actionable Mutations

EP. 2: Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP. 3: Exploring the TROPION-Lung04 Study

EP. 4: Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP. 5: Navigating Between ADCs in NSCLC

EP. 6: Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP. 7: Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP. 8: MARIPOSA Study Insights

Now Viewing

EP. 9: Optimizing Therapy Selection in EGFR Mutant NSCLC

EP. 10: ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP. 11: Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP. 12: Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP. 13: Targeting of HER3: Insights from HERTHENA-Lung01

EP. 14: Challenges and Learnings from EVOKE-01

EP. 15: Key ADC Studies at ASCO 2024

EP. 16: Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP. 17: Patient Selection and Sequencing of NSCLC ADCs

How will you potentially select patients in frontline EGFR mutant advanced NSCLC for:
- Osimertinib monotherapy
- Osimertinib + chemotherapy
- Amivantamab + Lazertinib